Welcome to our dedicated page for Chemomab Therapeutics SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode Chemomab’s biotech jargon before the next catalyst? SEC documents for clinical-stage firms can top 200 pages of scientific data, dilution math, and regulatory fine print. Chemomab Therapeutics’ filings are no exception—each 10-K details R&D spend on nebokitug (CM-101), while 8-Ks announce pivotal trial readouts and Orphan Drug milestones that can move the stock overnight.
Stock Titan turns those complex Chemomab reports into clear, actionable insight. Our AI-powered summaries highlight exactly where the burn-rate is disclosed, flag cash-runway warnings, and translate FDA terminology into plain English. Whether you need the latest “Chemomab quarterly earnings report 10-Q filing” or real-time alerts on “Chemomab insider trading Form 4 transactions”, you’ll find every document the moment it hits EDGAR.
Here’s what you can do on this page:
- Track Form 4 insider transactions in real time to see when executives add shares after Phase 2 data drops.
- Scan AI-generated overviews that make the annual 10-K understandable—perfect for anyone Googling “Chemomab annual report 10-K simplified.”
- Quickly locate 8-K material event disclosures on trial updates or new Fast Track designations.
- Dive into the proxy statement to review executive compensation without wading through legal text—ideal for “Chemomab proxy statement executive compensation” queries.
Stop scrolling through dense PDFs. Stock Titan’s expert analysis, AI-powered summaries, and comprehensive, real-time feed of “Chemomab SEC filings explained simply” let you focus on what matters: assessing clinical progress, monitoring dilution risk, and spotting opportunity before the market reacts.
Chemomab Therapeutics Ltd. has a disclosed beneficial owner, Erik Otto, who holds 1,690,000 American Depositary Shares (ADSs), representing 8.1% of the ADS class. Each ADS represents twenty ordinary shares.
Mr. Otto reports sole voting and sole dispositive power over these ADSs and certifies the holdings were not acquired to change or influence control of the issuer. The ownership percentage is stated based on the issuer's count of outstanding ADSs.
Morgan Stanley and subsidiary file Schedule 13G/A (Amendment 1) for Chemomab Therapeutics (CMMB) covering an ownership change effective 07/31/2025.
- Morgan Stanley reports 13,213,260 ordinary shares/ADS held with shared voting & dispositive power, equal to 3.2 % of Chemomab’s outstanding class.
- Morgan Stanley & Co. LLC reports 9,275,360 shares (shared voting & dispositive power) representing 2.2 % of the class.
- Both filers certify that they have ceased to be beneficial owners of more than 5 % of the issuer’s equity, triggering this amendment.
- Reporting persons are classified as HC/CO (holding company) and BD/CO (broker-dealer) under Item 3.
- No other persons have sole voting or dispositive authority; all powers are shared within the Morgan Stanley reporting units.
- The filing includes a Joint Filing Agreement (Ex. 99.1) and Item 7 subsidiary information (Ex. 99.2).
The amendment signals a reduction of Morgan Stanley’s aggregate position below the 5 % regulatory threshold, though the group still retains a meaningful minority stake.
Schedule 13G filing dated 06/30/2025 shows Morgan Stanley and subsidiary Morgan Stanley & Co. LLC have exceeded the 5 % threshold in Chemomab Therapeutics Ltd. (CMMB).
- Morgan Stanley reports 32,282,680 ordinary shares/ADS, representing 8.4 % of the outstanding class.
- Morgan Stanley & Co. LLC separately holds 28,786,680 shares or 7.5 %.
- Both entities report shared voting and dispositive power; no sole authority is listed.
- Filed under Rule 13d-1(b) as a broker-dealer/holding company, signalling a passive investment rather than a control bid.
- Cover pages classify the parent as “HC, CO” and the subsidiary as “BD, CO.”
- Signatures by authorised signatory Christopher O’Hara are dated 08/07/2025.
The disclosure increases institutional visibility and liquidity for CMMB but contains no operational or strategic changes.
OrbiMed Israel and affiliated entities have filed Amendment No. 5 to Schedule 13D reporting their exit from a significant ownership position in Chemomab Therapeutics Ltd (NASDAQ: CMMB). The filing indicates that following a major transaction, the reporting persons have ceased to be beneficial owners of more than 5% of the company's shares.
Key details of the transaction and current holdings:
- On June 18, 2025, OrbiMed Israel Partners (OIP) sold 1,610,000 American Depositary Shares at $1.10 per ADS
- Current holdings include 131,273 ADSs, 28,817 Warrants, and 809,717 Pre-Funded Warrants
- Total beneficial ownership now represents approximately 4.8% of outstanding shares
The reporting group includes OrbiMed Israel GP Ltd, OrbiMed Israel BioFund GP Limited Partnership, Carl L. Gordon, and Erez Chimovits. The holders maintain registration rights for their remaining securities under a previously established Registration Rights Agreement.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
